Topics

MPEG LA Announces Peer Reviewed Article Featured in Nucleic Acid Therapeutics

08:00 EDT 2 Oct 2019 | Businesswire
MPEG LA, LLC

Article details the use of multimeric oligonucleotides to improve intracellular conjugate delivery

World technology licensing leader MPEG LA today announced publication of a peer reviewed article in the October 2019 issue of Nucleic Acid Therapeutics on MPEG LA’s proprietary Increscent Therapeutics™ ligand-directed multiple payload oligonucleotide delivery platform.

“MPEG LA is proud to chart new territory with its development of a technology platform enabling drug developers to use oligonucleotide therapies to address new targets including cancer and those affecting the central nervous system,” said MPEG LA President and CEO Larry Horn.

According to principal author and innovator Dr. Jonathan Miles Brown, “The article concludes that delivery of multimeric oligonucleotide therapeutic agents to modulate gene expression or translation using MPEG LA’s Increscent Therapeutics™ may be of critical importance for effectively targeting cell/receptor types where ligand affinity, receptor copy number, or internalization rates are insufficient, as well as diseases where knockdowns of multiple genes or pathways are required.”

“In a departure from MPEG LA’s traditional pool licensing model that revolutionized licensing in the consumer electronics industry, MPEG LA’s Increscent Therapeutics™ platform is available for exclusive or nonexclusive licensing to the biopharma industry and poised to unlock and advance new healthcare opportunities,” said Kristin Neuman, MPEG LA’s Executive Director, Biotechnology Licensing.

An on-line version of the Nucleic Acid Therapeutics article “Ligand Conjugated Multimeric siRNAs Enable Enhanced Uptake and Multiplexed Gene Silencing” by Jonathan M. Brown, James E. Dahlman, Kristin K. Neuman, Carla A.H. Prata, Monika C. Krampert, Philipp M. Hadwiger and Hans-Peter Vornlocher may be found here.

Additional information about MPEG LA’s Increscent Therapeutics™ platform may be found here.

MPEG LA, LLC

MPEG LA is the world’s leading provider of one-stop licenses for standards and other technology platforms. Starting in the 1990s, it pioneered the modern-day patent pool helping to produce the most widely used standards in consumer electronics history and is expanding access to other groundbreaking technologies including electric vehicle charging and CRISPR. In addition, MPEG LA has developed Increscent Therapeutics™, a delivery platform for oligonucleotide therapeutics, which is available for licensing. MPEG LA has operated licensing programs for a variety of technologies consisting of about 22,000 patents in 90 countries with some 250 patent holders and more than 6,000 licensees. By assisting users with implementation of their technology choices, MPEG LA offers licensing solutions that provide access to fundamental intellectual property, freedom to operate, reduced litigation risk and predictability in the business planning process. For more information, go to www.mpegla.com.

Tom O’Reilly
MPEG LA, LLC
Tel: 303.200.1710
toreilly@mpegla.com

NEXT ARTICLE

More From BioPortfolio on "MPEG LA Announces Peer Reviewed Article Featured in Nucleic Acid Therapeutics"

Quick Search

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...